Records containing: Multidrug Resistant Tuberculosis
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2025-04-06Innovating(IN) Shorter(S), All- Oral, Precised(P), Individualized(I) Treatment Regimen(RE) for Rifampicin Resistant Tuberculosis(INSPIRE-TB)
-
CLINICAL_TRIALS study record update · 2025-02-03Evaluation of the Early Bactericidal Activity of Tedizolid and Linezolide Against Mycobacterium Tuberculosis
-
CLINICAL_TRIALS study record update · 2024-11-12Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T) (TB-TRUST)-PLUS
-
CLINICAL_TRIALS study record update · 2024-11-12Refining Multidrug Tuberculosis Treatment with the Ultra Short All Oral Regimen
-
CLINICAL_TRIALS study record update · 2024-05-29Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2022-07-07Safety and Effectiveness of Delamanid-containing Regimen for Treatment of Patients With Multidrug-resistant Tuberculosis in China
-
CLINICAL_TRIALS study record update · 2021-10-15Sequencing Mycobacteria and Algorithm-determined Resistant Tuberculosis Treatment Trial
-
CLINICAL_TRIALS study record update · 2021-09-29Evaluating a New Treatment Regimen for Patients With Multidrug-resistant TB (MDR-TB) - a Prospective Open-label Randomised Controlled Trial
-
CLINICAL_TRIALS study record update · 2020-11-23Phase 2, Open-label, Multiple-dose Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Delamanid (OPC-67683) in Pediatric Multidrug-resistant Tuberculosis Patients on Therapy With an Optimized Background Regimen of Anti-tuberculosis Drugs Over a 6-Month Treatment Period
-
CLINICAL_TRIALS study record update · 2020-07-23Multidrug Resistant Tuberculosis Close Contacts Tracing in China
-
CLINICAL_TRIALS study record update · 2018-07-30GRACE-TB：NGS-guided Regimens of Anti-tuberculosis Drugs for the Control and Eradication of MDR-TB
-
CLINICAL_TRIALS study record update · 2018-01-30Phase 1, Open-label, Multiple-dose, and Age De-escalation Trial to Assess the Pharmacokinetics, Safety and Tolerability of Delamanid (OPC 67683) in Pediatric Multidrug-resistant Tuberculosis Patients on Therapy With an Optimized Background Regimen of Anti-tuberculosis Drugs
-
CLINICAL_TRIALS study record update · 2015-07-14Effectiveness of a Simplified Short Regimen for Multidrug Resistant Tuberculosis Treatment in Karakalpakstan, Uzbekistan
-
CLINICAL_TRIALS study record update · 2014-04-23Optimization of MDR-TB Treatment Regimen Based on the Molecular Drug Susceptibility Results of Pyrazinamide
-
CLINICAL_TRIALS study record update · 2014-02-24A Phase 2a, Randomized, 2-Arm, Open-Label, Clinical Trial of the Efficacy of Linezolid Combined With Antituberculous Therapy in Subjects With Extensively Drug-Resistant (XDR) Pulmonary Tuberculosis